I’d start with their balance sheet... over US$120m cash but they have around US$90 in debt. So not much room to move in that sense... any major delays will mean more capital required.
the key delay could be (not likely) a knock back from the FDA on Ryoncil.. that decision is due no later than 30 Sept.
there are some phase 3 trials (back pain, CHF and COVID)due to read out before years end.. if they fail, then that will mean the share price will go down..
I’d start with their balance sheet... over US$120m cash but they...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.060(5.85%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.10 | $1.02 | $6.406M | 6.038M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 313712 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
0.060 ( 5.29 %) |
||||
| Open | High | Low | Volume | ||
| $1.03 | $1.10 | $1.02 | 928883 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| MSB (ASX) Chart |